Funding
PI Tenbusch
- Deutsche Forschungsgemeinschaft DFG-RTG2504 - “Novel antiviral approaches: from small molecules to immune intervention”
- DFG-Projektförderung TE1004/1- „RSV enhanced disease after adenoviral vector immunization“
- BMBF- Förderung von konfirmatorischen präklinischen Studien: RSV-Protect (01KC2007A)
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) – Teilprojekte (A101 und A90)
- VetBioNet. a European Union’s Horizon 2020 research and innovation programme, grant agreement No 731014.
- ISIDORe-BroProMIS
- Bayerisches Staatsministerium für Wissenschaft und Kunst - Bayerischer Forschungsverbund FOR-COVID
- Doktor Robert Pfleger Stiftung- „Signalmoleküle der angeborenen Immunantwort als genetische Adjuvantien bei adenoviralen Vektor-immunisierungen gegen das Respiratorische Synzytial Virus (RSV)“
PI Lapuente
- ELAN pilot project, Interdisziplinäres Zentrum für Klinische Forschung, project P071
- Doktor Robert Pfleger Stiftung
- Junior project, Interdisziplinäres Zentrum für Klinische Forschung, project J100
Collaborations
PI Tenbusch
- Prof. Thomas Winkler, Department of Biology, Division of Genetics, FAU Erlangen-Nürnberg, Germany.
- PD Kilian Schober, Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Germany.
- Prof. Christian Bogdan, Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Germany.
- PD Thomas Grunwald, Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology, IZI, Leipzig, Germany.
- Prof. Thomas Krey, Institute of Biochemistry, University of Luebeck, Germany
- Prof. Hartmut Hengel, Institute of Virology, University of Freiburg, Freiburg, Germany.
- Prof. Ulrike Protzer, Institute of Virology, Technical University of Munich / Helmholtz Zentrum München, Germany;
- Prof. Oliver Cornely, University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Germany
- Prof. Elma Tchilian, Host Responses, The Pirbright Institute, Pirbright, United Kingdom
- PD Jürgen Held, Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Germany.
- Prof. Thomas Harrer, Infectious Disease and Immunodeficiency Section, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Germany.
- PD Andreas Kremer, Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
- Dr. Anita Kremer, Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Germany.
- Prof. Georg Schett, Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Germany
- PD Wibke Bayer, Institute of Virology, University Hospital Essen, Germany
- Dr. Christiane Stahl-Henning, Unit of Infection Models at the German Primate Center (DPZ), Göttingen, Germany
- Dr. Gerrit Koopman/ Dr. Petra Mooji, Department of Virology, Biomedical Primate Research Centre (BPRC). Rijswijk, Netherlands
- Prof. Ralf Wagner, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Germany.
- Dr. Christian Thirion/ Dr. Silke Schroedel, SIRION Biotech GmbH, Martinsried, Germany
PI Lapuente
- Prof. Claudia Gravekamp, Department of Microbiology & Immunology, Albert Einstein College of Medicine, New York, USA
- Prof. Udo Gaipl, Dr. Benjamin Frey, Dr. Michael Rückert, Translational Radiobiology, Department of Radiation Oncology, University Hospital Erlangen, Germany
- Prof. Takeshi Kobayashi, Department of Virology, Research Institute for Microbial Diseases, Osaka University, Japan
